tem 5.02. Departure of Directors or Certain Officers; Election of Directors;
On May 2, 2008, Charles J. Homcy, M.D., currently a member of the Board of Directors (the "Board") of Kosan Biosciences Incorporated (the "Company"), informed the Company of his resignation from the Board, effective May 24, 2008. Dr. Homcy currently serves in the class of directors whose term expires at the Company's 2010 annual meeting of stockholders.
(I wonder, why he left so abrubtly?)
Charles Homcy, M.D., has served as a director since April 2003. Since November 2003, Dr. Homcy has served as Chief Executive Officer and a director of Portola Pharmaceuticals, Inc., a biopharmaceutical company. From January 2003 to November 2003, Dr. Homcy served as Senior Research and Development Advisor of Millennium Pharmaceuticals, a biopharmaceutical company. From February 2002 to December 2002, Dr. Homcy served as the President of Research and Development at Millennium Pharmaceuticals. From 1995 to February 2002, he served as Executive Vice President, Research and Development of COR Therapeutics, Inc., a biotechnology company, where he served as a member of the board of directors from 1998 to February 2002. From 1994 to March 1995, Dr. Homcy was President of the Medical Research Division of American Cyanamid Company-Lederle Laboratories, a pharmaceutical company (now a division of Wyeth-Ayerst Laboratories). From 1990 to 1994, Dr. Homcy was Executive Director of the Cardiovascular and Central Nervous System Research Section at Lederle Laboratories. Dr. Homcy is a member of the board of directors of Millennium Pharmaceuticals, Cytokinetics, Incorporated and Geron Corporation. Dr. Homcy received a B.A. and an M.D. from the Johns Hopkins University.
|
